S
NBIX icon

Sachetta’s Neurocrine Biosciences NBIX Stock Holding History

Sachetta’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.94K Buy
59
+5
+9% +$742 ﹤0.01% 443
2026
Q1 		$7.11K Hold
54
– – ﹤0.01% 540
2025
Q4 		$7.66K Hold
54
– – ﹤0.01% 455
2025
Q3 		$7.58K Hold
54
– – ﹤0.01% 517
2025
Q2 		$6.79K Buy
54
+42
+350% +$4.82K ﹤0.01% 522
2025
Q1 		$1.33K Sell
12
-24
-67% -$3.04K ﹤0.01% 879
2024
Q4 		$4.91K Buy
36
+24
+200% +$2.97K ﹤0.01% 591
2024
Q3 		$1.38K Hold
12
– – ﹤0.01% 971
2024
Q2 		$1.7K Hold
12
– – ﹤0.01% 893
2024
Q1 		$1.58K Hold
12
– – ﹤0.01% 785
2023
Q4 		$1.58K Buy
+12
New +$1.38K ﹤0.01% 785

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sachetta's NBIX Position: Q2 2026 in Review

Sachetta increased its Neurocrine Biosciences (NBIX) stake by 9.3% in Q2 2026, buying an estimated $742 and bringing the position to 59 shares worth $9.94K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Sachetta first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sachetta held 59 shares of Neurocrine Biosciences worth $9.94K as of Q2 2026.
  • Sachetta bought 5 Neurocrine Biosciences shares in Q2 2026, an estimated $742.
  • Neurocrine Biosciences made up ﹤0.01% of Sachetta's portfolio in Q2 2026, its #443 holding.
  • Sachetta first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.